Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Brokerages

Immunome, Inc. (NASDAQ:IMNM) has been given an average rating of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $28.83.

IMNM has been the subject of a number of recent research reports. Piper Sandler decreased their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Monday. Finally, Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 66,057 shares of Immunome stock in a transaction on Thursday, November 21st. The stock was purchased at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the purchase, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO Philip Tsai bought 21,000 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were acquired at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the transaction, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 102,862 shares of company stock valued at $978,045. 8.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. Marshall Wace LLP raised its holdings in shares of Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares during the period. Janus Henderson Group PLC increased its position in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after buying an additional 324,614 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares during the period. Victory Capital Management Inc. lifted its position in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares during the last quarter. Finally, AXA S.A. bought a new position in shares of Immunome during the 2nd quarter worth $2,174,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Price Performance

NASDAQ:IMNM opened at $9.38 on Wednesday. Immunome has a one year low of $8.97 and a one year high of $30.96. The company has a market cap of $585.47 million, a PE ratio of -1.16 and a beta of 1.90. The firm has a 50-day moving average of $11.72 and a 200-day moving average of $12.98.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.